THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS

被引：0
|
作者：
Herter, S. [1 ]
Del Giudice, I. [2 ]
Schmidt, C. [1 ]
Fauti, T. [1 ]
Klein, C. [3 ]
Umana, P. [1 ]
Dyer, M. J. S. [4 ]
Foa, R. [2 ]
Grau, R. [1 ]
机构：
[1] Glycart Biotechnol AG, Schlieren, Switzerland
[2] Univ Roma La Sapienza, Rome, Italy
[3] Roche Diagnost GmbH, Penzberg, Germany
[4] Univ Leicester, Leicester, Leics, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0910
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [21] CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
    Jak, Margot
    van Bochove, Gregor G. W.
    Reits, Eric A.
    Kallemeijn, Wouter W.
    Tromp, Jacqueline M.
    Umana, Pablo
    Klein, Christian
    van Lier, Rene A. W.
    van Oers, Marinus H. J.
    Eldering, Eric
    BLOOD, 2011, 118 (19) : 5178 - 5188
  • [22] Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
    Alduaij, Waleed
    Ivanov, Andrei
    Honeychurch, Jamie
    Cheadle, Eleanor J.
    Potluri, Sandeep
    Lim, Sean H.
    Shimada, Kazuyuki
    Chan, Claude H. T.
    Tutt, Alison
    Beers, Stephen A.
    Glennie, Martin J.
    Cragg, Mark S.
    Illidge, Tim M.
    BLOOD, 2011, 117 (17) : 4519 - 4529
  • [23] Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity
    Herting, Frank
    Herter, Sylvia
    Friess, Thomas
    Lehmann, Christian
    Bacac, Marina
    Dangl, Markus
    Klein, Christian
    BLOOD, 2014, 124 (21)
  • [24] Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
    Erting, Frank H.
    Friess, Thomas
    Bader, Sabine
    Muth, Gunter
    Hoelzlwimmer, Gabriele
    Rieder, Natascha
    Umana, Pablo
    Klein, Christian
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2151 - 2160
  • [25] Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
    Sampath, Deepak
    Herter, Sylvia
    Ingalla, Ellen
    Herting, Frank
    Bacac, Marina
    Nannini, Michelle
    Fairbrother, Wayne J.
    Klein, Christian
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [26] Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies
    Beurskens, Frank J.
    Ruuls, Sigrid R.
    Engelberts, Patrick J.
    Vink, Tom
    Mackus, Wendy J.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    BLOOD, 2008, 112 (10) : 4354 - 4355
  • [27] GA101, a novel humanized type IICD20 antibody with glycoengineered Fe and enhanced cell death induction, mediates superior efficacy in a variety of NHL xenograft models in comparison to rituximab
    Friess, Thomas
    Gerdes, Christian
    Nopora, Adam
    Patre, Monika
    Preiss, Susanne
    van Puijenbroek, Erwin
    Schnell, Christine
    Bauer, Sabine
    Umana, Pablo
    Klein, Christian
    BLOOD, 2007, 110 (11) : 691A - 692A
  • [28] The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
    Marinov, Anthony D.
    Wang, Haowei
    Bastacky, Sheldon I.
    van Puijenbroek, Erwin
    Schindler, Thomas
    Speziale, Dario
    Perro, Mario
    Klein, Christian
    Nickerson, Kevin M.
    Shlomchik, Mark J.
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 848 - 857
  • [29] Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263
    Herting, Frank
    Bader, Sabine
    Umana, Pablo
    Klein, Christian
    BLOOD, 2010, 116 (21) : 1597 - 1597
  • [30] Different Pattern of Expression of CD52, CD20 and CXCR-4 in Peripheral Blood, Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia (B-CLL)
    Jaksic, Ozren
    Gizdic, Branimir
    Veic, Tajana Stoos
    Jaksic, Vlatka Pandzic
    Kusec, Rajko
    Pejsa, Vlatko
    Jaksic, Branimir
    BLOOD, 2011, 118 (21) : 1657 - 1657
12345